filgrastim + autologous cord blood mononuclear cells

This investigational cell therapy approach is being developed by Hanyang University Seoul Hospital for the treatment of cerebral palsy in children. The treatment protocol involves the combination of granulocyte-colony stimulating factor (G-CSF), specifically filgrastim (Leucostim), followed by the intravenous infusion of autologous cord blood mononuclear cells (CB-MNCs). The G-CSF is administered to mobilize endogenous stem cells and provide neuroprotective support, while the autologous cord blood cells—which contain hematopoietic and other multipotent stem cells—are intended to migrate to the site of brain injury. Once there, they are hypothesized to promote neuronal regeneration and functional repair through paracrine effects, including the secretion of neurotrophic factors and anti-inflammatory cytokines. Clinical evaluation is currently focused on children aged 2 to 10 years with non-severe cerebral palsy in Phase II trials.

Other names

G-CSF and autologous cord blood infusionCB-MNC and G-CSF therapyautologous cord blood-Hanyang University Seoul Hospital-cerebral palsy